TY - JOUR T1 - Anti-leukemic Activity of AIU2008 in FLT3-ITD-positive Acute Myeloid Leukemia JF - Anticancer Research JO - Anticancer Res SP - 731 LP - 737 DO - 10.21873/anticanres.14824 VL - 41 IS - 2 AU - HYO JEONG KIM AU - HWANI RYU AU - HYUN-KYUNG CHOI AU - JIE-YOUNG SONG AU - SANG-GU HWANG AU - JIYEON AHN Y1 - 2021/02/01 UR - http://ar.iiarjournals.org/content/41/2/731.abstract N2 - Background/Aim: FMS-like tyrosine kinase 3 (FLT3) is a class III receptor tyrosine kinase involved in signal transduction underlying survival, proliferation, and differentiation of hematopoietic cells. An internal tandem duplication (ITD) in FLT3 in the juxtamembrane domain is a common mutation causing human acute myeloid leukemia (AML) and activates constitutive signaling. Materials and Methods: We evaluated the novel FLT3 inhibitor 5-(4-fluorophenyl)-N-(naphthalen-1-yl)oxazol-2-amine (AIU2008) for the treatment of AML. Results: AIU2008 was designed by modifying FLT3 inhibitor 7c, and showed improved anti-leukemic efficacy in FLT3-ITDā€“positive AML cells. Specifically, AIU2008 inhibited cell growth and apoptotic death. In addition, AIU2008 down-regulated DNA repair genes involved in homologous recombination and non-homologous end joining. It contributed to the synergistic inhibition of AML cell growth in combination treatment with PARP inhibitors. Conclusion: AIU2008 is a promising FLT3 targeting agent, and may be used in combination with PARP inhibitors for the treatment of AML. ER -